Treatment of digital vasospastic disease with the calcium-entry blocker nifedipine
- PMID: 6702493
- DOI: 10.1111/j.0954-6820.1984.tb04983.x
Treatment of digital vasospastic disease with the calcium-entry blocker nifedipine
Abstract
Eight patients with vasospastic disease of the digital arteries were treated with the calcium-entry blocker nifedipine (capsules), 10 mg t.i.d. and 20 mg t.i.d. The degree of cold-induced digital vasospasm after local cooling of the finger to 15 and 10 degrees C, measured by strain-gauge technique, was significantly decreased by nifedipine. The degree of reduction was dose-dependent. All patients improved symptomatically. The side-effects of the drug were minor but became more prominent when the dose was increased. We conclude that nifedipine is a useful agent in the treatment of digital vasospastic disease.
Similar articles
-
The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm. A double-blind crossover study versus placebo.Acta Med Scand. 1987;221(1):53-60. doi: 10.1111/j.0954-6820.1987.tb01245.x. Acta Med Scand. 1987. PMID: 3551507 Clinical Trial.
-
Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon).Eur Heart J. 1983 May;4 Suppl C:123-9. doi: 10.1093/eurheartj/4.suppl_c.123. Eur Heart J. 1983. PMID: 6352267 Clinical Trial.
-
[The use of calcium antagonists in the treatment of ocular circulation symptoms in the framework of a vasospastic syndrome].Schweiz Med Wochenschr. 1988 Feb 13;118(6):201-2. Schweiz Med Wochenschr. 1988. PMID: 3363311 German.
-
Structure and function of small arteries of essential hypertensive patients following chronic treatment with once-a-day nifedipine.Cardiology. 1997;88 Suppl 3:20-6. doi: 10.1159/000177502. Cardiology. 1997. PMID: 9397289 Review.
-
Nifedipine.Nurs Times. 2005 Jul 19-25;101(29):31. Nurs Times. 2005. PMID: 16052940 Review. No abstract available.
Cited by
-
Clinical and rheological effects of nifedipine in Raynaud's phenomenon.Br J Clin Pharmacol. 1986 Oct;22(4):449-54. doi: 10.1111/j.1365-2125.1986.tb02916.x. Br J Clin Pharmacol. 1986. PMID: 3533127 Free PMC article. Clinical Trial.
-
The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.Cardiovasc Drugs Ther. 1989 Jun;3(3):397-401. doi: 10.1007/BF01858110. Cardiovasc Drugs Ther. 1989. PMID: 2535054 Clinical Trial.
-
Use of nifedipine in hypertension and Raynaud's phenomenon.Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:935-40. doi: 10.1007/BF02018296. Cardiovasc Drugs Ther. 1990. PMID: 2076403 Review.
-
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.Drugs. 1985 Sep;30(3):182-274. doi: 10.2165/00003495-198530030-00002. Drugs. 1985. PMID: 2412780 Review. No abstract available.
-
Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.Eur J Clin Pharmacol. 1986;31(4):387-9. doi: 10.1007/BF00613511. Eur J Clin Pharmacol. 1986. PMID: 3816916 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical